Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20555479 | 1.00 | ALDH1A1 (0.33) | ALDH1A1PKMPOLBL3MBTL1LMNA | |
| SCHEMBL20555145 | 0.82 | ALDH1A1 (0.32) | ALDH1A1PKMPOLBL3MBTL1LMNA | |
| SCHEMBL20555148 | 0.82 | ALDH1A1 (0.32) | ALDH1A1PKMPOLBL3MBTL1LMNA | |
| SCHEMBL20555088 | 0.81 | POLB (0.36) | ALDH1A1PKMPOLBL3MBTL1LMNA | |
| SCHEMBL20555412 | 0.81 | POLB (0.36) | ALDH1A1PKMPOLBL3MBTL1LMNA | |
| SCHEMBL20555294 | 0.80 | POLB (0.34) | ALDH1A1PKMPOLBL3MBTL1MEN1 | |
| SCHEMBL20555292 | 0.80 | POLB (0.34) | ALDH1A1PKMPOLBL3MBTL1MEN1 | |
| SCHEMBL20555397 | 0.78 | PKM (0.33) | ALDH1A1PKMPOLBL3MBTL1MEN1 | |
| SCHEMBL20555381 | 0.78 | PKM (0.33) | ALDH1A1PKMPOLBL3MBTL1MEN1 | |
| SCHEMBL20555333 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, MAPT | ALDH1A1 3433/4885PKM 232/4885POLB 1344/4885 |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | ALDH1A1 3312/4885PKM 234/4885POLB 1369/4885 |
| US-11214565-B2 | Compound, compositions, and methods | LRRK2, PARK7, MAPT | ALDH1A1 3433/4885PKM 232/4885POLB 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.